Ovid Therapeutics Inc. · NASDAQ:OVID
Ovid Therapeutics — Investor Presentation (May 2021)
18 slides from Ovid Therapeutics's investor presentation, May 18, 2021
Slide 1: Ovid Therapeutics Corporate Overview
Ovid Therapeutics Corporate Overview May 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 May 2021 Exhibit 99.1
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and s
Slide 3: Bold vision to build a unique company in rare CNS disorders
©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 3 boldvision To build a unique company in rare disorders of the CNS Innovation Patients Execution Clear Vision Enabled by a Strong Foundation May 2021 The Right Team, Experience and Track-Record + Adequate Capital Focused on
Slide 4: Pipeline Focused on Advancing Treatment of Rare Diseases
Phase 3 Planned Initiation Mid-2021 Phase 3 Planned Initiation Mid-2021 Anticipate filing three INDs in three years, beginning 1H 2022 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 4 January 2021 May 2021 Pipeline Focused on Advancing Treatment of Rare Diseases
Slide 5: Transformative $856M+ Agreement with Takeda (soticlestat)
5 May 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Transformative $856M+ Agreement with Takeda (soticlestat) Regulatory Milestones Regulatory milestones Takeda initially funding two comprehensive pivotal trials (LGS and Dravet) Commercial Milestones/Royalties Commercial sales milestones p
Slide 6: 2021 Strategic Priorities and Execution
2021 Strategic Priorities and Execution ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 6 May 2021 Accelerate pre-clinical assets and anticipate filing three INDs from 2022 to 2025 Enhance pipeline and capabilities with BD IMPLEMENTATION STEPS Advance next-generation neuroscience pipeline Compreh
Slide 7: Advance Next-Generation Neuroscience Pipeline
Focus on ecosystem of rare neurological diseases with high unmet need Develop novel first-in-class / best-in-class therapeutics Create a customized disease approach leveraging deep understanding of underlying pathology Collaborate with the patient community, KOLs, and other external innovators to ac
Slide 8: OV329: Highly Potent Inhibitor of GABA Aminotransferase
OV329: Highly Potent Inhibitor of GABA Aminotransferase ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 8 May 18, 2021 Mechanism: Highly potent GABA aminotransferase (GABA-AT) oral small molecule inhibitor Development status: IND enabling studies are underway, IND expected 1H 2022 Opportunity: Cr
Slide 9: OV329 Appears Active in Models of Drug-Resistant Seizures
OV329 Appears Active in Models of Drug-Resistant Seizures ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 9 May 18, 2021 May 2021 NMDA Model described by Shi et al., 2014 (PMID 26600368) Orally delivered OV329 as effective as injectable SOC in infantile spasms model
Slide 10: OV882: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome
OV882: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome (AS) ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 10 May 18, 2021 May 2021 Mechanism: Short hairpin RNA that interacts with non-coding RNA to inhibit the silencing of paternal UBE3A gene Development status: POC* activity
Slide 11: OV882 Approach to the Treatment of Angelman Syndrome
OV882 Approach to the Treatment of Angelman Syndrome ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 11 May 18, 2021 May 2021 DESCRIPTION OF APPROACH BENEFITS AND DRAWBACKS RNAI APPROACHES TO TREATING ANGELMAN SYNDROME DISEASE STATE ASO APPROACH Angelman syndrome is caused by a mutation in the ma
Slide 12: OV882 Appears Active in AS Neuron Cell Model
OV882 Appears Active in AS Neuron Cell Model ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 12 May 18, 2021 May 2021 SCRAM shRNA OV882 UBE3A-ATS UBE3A mRNA Relative RNA Expression shRNA-OV882 Effects on UBE3A-Antisense and UBE3A Expression (iPSC-AS neurons) OV882 demonstrates activity in AS neur
Slide 13: OV815: Potential Advanced Genetic Therapy for KAND
OV815: Potential Advanced Genetic Therapy for KAND and Other KIF-associated Diseases ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 13 May 18, 2021 May 2021 Mechanism: Genetic/molecular approach targeting KIF1A Development status: Currently in screening stage for aptamer and gene silencing techn
Slide 14: OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily
OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 14 May 18, 2021 KIF1A (Kinesin 3 Family Member) May 2021 Impact of KIF1A on neurotransmission KIF1A is a motor protein that transports cargo for neurons Disruption of cargo
Slide 15: Targeting CNS Technology and Genetic Therapies
Targeting CNS Technology and Genetic Therapies 15 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Neuroscience Rare neurological, neurometabolic, ophthalmic disorders Actionable assets near IND or later Complementary to existing pipeline and strategy Leverage core capabilities in rare CNS disease
Slide 16: Strong Balance Sheet Supports Strategy
Strong Balance Sheet Supports Strategy ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 16 May 18, 2021 May 2021 Strong balance sheet: $233M in cash and cash equivalents as of 3/31/21 No further financial obligations for soticlestat, significant downstream economics if soticlestat is approved Expe
Slide 17: Leadership Team With Required Track Record
©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 17 Jeremy Levin DPhil, MB Bchir Chairman, CEO Amit Rakhit MD, MBA President, CMO Jason Tardio MBA Chief Commercial Officer Jeffrey Rona Chief Business Officer Thomas Perone JD, MBA GC, Corporate Secretary, and CCO Leadership Team With Required Track
Slide 18: Thank you
Thank you May 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 18 January 2021 May 2021